



BRET M. DICKEY, Ph.D.
CURRICULUM VITAE

Executive Vice President
Compass Lexecon
1111 Broadway, Suite 1500
Oakland, CA 94607
(510) 285-1249
bdickey@compasslexecon.com

SUMMARY

Bret Dickey is an Executive Vice President at Compass Lexecon and is based in Oakland. His areas of expertise include industrial organization, public economics, health economics, and econometrics and quantitative methods. He has over 20 years of experience applying economic and quantitative analysis to areas including antitrust, intellectual property, class certification, damages, and public policy. An important focus of his work has been the health care and life sciences industries, particularly pharmaceuticals and biologics, but also vaccines, medical equipment, laboratory and research equipment, and Medicare and Medicaid. His experience also spans a broad range of other industries including air transportation, financial services, housing, insurance, sports, technology, and ticketing services. Dr. Dickey has testified in federal and state courts and before the U.S. House of Representatives. He serves on FTI Consulting’s Pro Bono Advisory Committee and has an active pro bono practice.

Dr. Dickey received an M.A. and a Ph.D. in Economics from Stanford University and a B.A. in Economics from the University of Pennsylvania. Prior to joining Compass Lexecon, he held positions at LECG, the SPHERE Institute, and the Council of Economic Advisers.

EDUCATION

Ph.D., Economics, STANFORD UNIVERSITY, Stanford, CA, 1999
Fields of Specialization: Industrial Organization, Public Finance, Econometrics
Dissertation: “Participation Dynamics in Low-Income Housing Assistance Programs”
M.A., Economics, STANFORD UNIVERSITY, Stanford, CA, 1995
B.A., Economics (summa cum laude, with honors), UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA, 1992

PROFESSIONAL EXPERIENCE

COMPASS LEXECON (formerly Competition Policy Associates), Oakland, CA, 2006 – present
Executive Vice President
Co-Head, Oakland Office
Member, FTI Consulting Pro Bono Advisory Committee
Senior Vice President (2007-2013), Vice President (2006-2007)

LECG, Emeryville, CA, 1999-2006

Principal

Senior Managing Economist (2003-2005), Managing Economist (2001-2002), Senior Economist (1999-2000)

STANFORD UNIVERSITY, Department of Economics, Stanford, CA, 1994-1997, 1999
Research Assistant

THE SPHERE INSTITUTE, Palo Alto, CA, 1997-1998
Research Associate

STANFORD UNIVERSITY, Department of Economics, Stanford, CA, 1997
Teaching Assistant, Introduction to Econometrics

AMERICAN ECONOMIC ASSOCIATION, Summer Minority Program, Stanford, CA, 1995
Teaching Assistant, Applied Microeconomic Analysis and Introduction to Econometrics

COUNCIL OF ECONOMIC ADVISERS, Executive Office of the President, Washington, DC, 1992-1993
Research Assistant

PUBLICATIONS

“Pharmaceutical Product Hopping: Is There a Role for Antitrust Scrutiny?” (with Kun Huang and Daniel L. Rubinfeld), *Antitrust Law Journal*, Vol. 82, Issue 2, 2019, pp. 679-699.

“Would the *Per Se* Illegal Treatment of Reverse Payment Settlements Inhibit Generic Drug Investment?” (with Daniel L. Rubinfeld), *Journal of Competition Law & Economics*, Vol. 8, Issue 3, 2012, pp. 615-625.

“Antitrust Class Certification: Towards an Economic Framework” (with Daniel L. Rubinfeld), *New York University Annual Survey of American Law* (part of symposium on Critical Directions in Antitrust), Vol. 66, Issue 3, 2011, pp. 459-486.

“An Economic Assessment of Patent Settlements in the Pharmaceutical Industry” (with Jonathan Orszag and Laura Tyson), *Annals of Health Law*, Vol. 19, Issue 2, Winter 2010, pp. 367-400.

“Patent Settlements In the Pharmaceutical Industry: Balancing Intellectual Property and Antitrust Concerns” (with Kelly Lear Nordby), *Trade Practices Law Journal*, Vol. 12, No. 3, September 2004, pp. 175-180.

“*De Facto* Exclusive Dealing and the *Concord Boat* Case” (with Michael P. Akemann), *Trade Practices Law Journal*, December 2001, pp. 281-286.

INVITED TESTIMONY AND PRESENTATIONS

American Bar Association, Pricing Conduct and Health Care and Pharmaceuticals Committees, “Pharmaceutical Product Hopping: What is the Role for Antitrust Enforcement?” February 25, 2020.

Los Angeles County Bar Association, Antitrust and Unfair Business Practices Section, “Beyond *FTC v. Actavis*: Recent and Emerging Issues at the Intersection of Antitrust and the Pharmaceutical Industry,” May 29, 2015.

Duke Law School, “New Approaches and Incentives in Drug Development,” November 22, 2013.

U.S. House of Representatives, Committee on the Judiciary, Subcommittee on Courts and

Competition Policy, Hearing on “Pay to Delay: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive?” June 3, 2009.

HONORS AND AWARDS

Lawyers’ Committee for Civil Rights of the San Francisco Bay Area, Robert G. Sproul, Jr. Award (for pro bono work), 2017

Stanford University, Center for Economic Policy Research, Olin Foundation Dissertation Fellowship, 1997-1998

Stanford University, Department of Economics, Outstanding Teaching Assistant Award (Honorable Mention), 1997

Stanford University, Graduate Fellowship, 1993-1994

Phi Beta Kappa, 1992

PROFESSIONAL AFFILIATIONS

American Bar Association (Associate)

American Economic Association